Table 5. Monte Carlo simulation* results: mean cost per patient treated and percentage of patients without PID† >(5th percentile, 95th percentile).
| Prevalence (%) gonorrhea | Strategy‡ | Prevalence of ciprofloxacin resistance = 0.1% |
Prevalence of ciprofloxacin resistance = 2% |
||
|---|---|---|---|---|---|
| $/patient treated | % patients without PID | $/patient treated | % patients without PID | ||
| 1 | ST1 | 27.34 (21.45, 33.23) | 99.92 (99.84, 99.96) | 27.44 (21.72, 33.64) | 99.92 (99.84, 99.96) |
| ST2 | 39.78 (30.45, 50.19) | 99.92 (99.83, 99.96) | 39.78 (30.57, 50.95) | 99.92 (99.84, 99.96) | |
| ST3 | 28.94 (22.92, 35.08) | 99.92 (99.84, 99.96) | 28.99 (23.25, 35.32) | 99.92 (99.84, 99.96) | |
| ST4 | 42.00 (31.38, 53.08) | 99.93 (99.84, 99.96) | 41.99 (32.23, 53.83) | 99.92 (99.84, 99.96) | |
| 10 | ST1 | 68.73 (46.22, 99.01) | 99.18 (98.41, 99.59) | 71.65 (47.04, 102.58) | 99.16 (98.38, 99.61) |
| ST2 | 77.34 (53.53, 106.86) | 99.23 (98.43, 99.63) | 77.29 (54.83, 110.64) | 99.19 (98.44, 99.61) | |
| ST3 | 70.37 (47.06, 98.72) | 99.18 (98.41, 99.60) | 70.33 (46.85, 101.75) | 99.17 (98.39, 99.61) | |
| ST4 | 79.69 (55.78, 109.48) | 99.23 (98.44, 99.80) | 79.68 (55.90, 110.87) | 99.21 (98.48, 99.63) | |
*Monte Carlo simulation involves specifying a probability distribution of values for model inputs (see Tables 2 and 3 for distributions used). A computer algorithm ran the model for 10,000 iterations. During each iteration, the computer algorithm selects input values from the probability distributions and calculates the output (e.g., cost per patient successfully treated). After the final run, the model provides results such as the mean, median, and 5th and 95th percentiles for each specified output. †PID, pelvic inflammatory disease, which can cause sequelae such as chronic pelvic pain, infertility, and ectopic pregnancy. ‡The strategies modeled were ST1: ciprofloxacin + culture-based tests + ciprofloxacin-susceptibility tests; ST2: ciprofloxacin + nonculture-based tests; ST3: ceftriaxone + culture-based tests + ceftriaxone-susceptibility tests; ST4: ceftriaxone + nonculture-based tests. See Table 1 and text for further details.